Low incidence of hepatotoxicity in a cohort of HIV patients treated with lopinavir/ritonavir.
We describe the hepatotoxicity encountered in a cohort of HIV-positive patients treated with lopinavir/ritonavir. We used the database from the SCOLTA project, an on-line pharmacovigilance programme involving 25 Italian infectious disease centres. A total of 755 patients were followed, over a mean observation period of 16 months. The incidence of severe events was low despite the high prevalence of patients co-infected with hepatitis virus at enrollment.
Bonfanti
Paolo
P
I Divisione di Malattie Infettive, Ospedale Luigi Sacco, Milan, Italy.
Ricci
Elena
E
Penco
Giovanni
G
Orofino
Giancarlo
G
Bini
Teresa
T
Sfara
Claudio
C
Miccolis
Sebastiano
S
Cristina
Giovanni
G
Quirino
Tiziana
T
D000293:Adolescent; D000328:Adult; D056486:Chemical and Drug Induced Liver Injury; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects*; D019694:Hepatitis B, Chronic / Q000150:complications; D019698:Hepatitis C, Chronic / Q000150:complications; D006801:Humans; D015994:Incidence; D007558:Italy / Q000453:epidemiology; D008107:Liver Diseases / Q000453:epidemiology; D061466:Lopinavir; D008297:Male; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing; D011744:Pyrimidinones / Q000009:adverse effects*; D019438:Ritonavir / Q000009:adverse effects*
D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir